Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials

Sexually Transmitted Diseases

Volumn 40, Issue 12, 2013, Pages 950-956

  Van Der Straten, Ariane ^a,b   Cheng, Helen ^a   Mensch, Barbara ^c   Friedland, Barbara ^c   Katzen, Lauren ^c   Littlefield, Sarah ^c   Buckley, Niall ^d   Espinoza, Lilia ^d   Keller, Marla J ^d   Herold, Betsy C ^d   Einstein, Mark H ^d,e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c POPULATION COUNCIL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; PLACEBO; POLYETHYLENE;

ADULT; ARTICLE; ASSAY; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DYE STAIN ASSAY; FEMALE; GEL; GYNECOLOGIC CARE; GYNECOLOGICAL AND OBSTETRIC MONITORING DEVICE; HUMAN; HUMAN EXPERIMENT; LIKERT SCALE; MEDICATION COMPLIANCE; NORMAL HUMAN; SELF REPORT; SENSITIVITY AND SPECIFICITY; SEXUAL INTERCOURSE; STAINING; ULTRAVIOLET LIGHT ASSAY; ULTRAVIOLET RADIATION;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS; COLORING AGENTS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UNITED STATES; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84888217627     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000053     Document Type: Article

References (29)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174
2. Padian NS, McCoy SI, Balkus JE, et al. Weighing the gold in the gold standard: Challenges in HIV prevention research. AIDS 2010; 24:621-635
3. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). CROI; March 3-6, 2013, 2013; Atlanta, G.A.
4. Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2010; 14:1124-1136
5. van der Straten A, Montgomery ET, Hartmann M, et al. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep 2013; 10:89-102
6. Wallace A, Thorn M, Maguire RA, et al. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 2004; 31:465-468
7. Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis 2011; 38:1050-1055
8. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 2007; 76:53-56
9. Moench TR, O'Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis 2012. Published ahead-of-print
10. Gengiah T, Mansoor L, Naidoo A, et al. The CAPRISA 004 'Wisebag': Enhancing Adherence Measurement in Microbicide Trials. Paper presented at: Microbicides 2010 Conference 2010; Pittsburgh, P.A.
11. Haberer JE, Kiwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS 2013
12. Haberer J, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 2010; 14:1340-1346
13. van der Straten A, Montgomery E, Pillay D, et al. Feasibility, performance, and acceptability of the Wisebagi for potential monitoring of daily gel applicator use in Durban, South Africa. AIDS Behav 2013; 17:640-648
14. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987
15. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: Current status and a reconceptualization. Curr Opin HIV AIDS 2012; 7:534-541
16. Abbott SA, Friedland BA, Sarna A, et al. An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. AIDS Behav 2013: 1-15
17. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005; 21: 845-853
18. Lu M, Safren S, Skolnik P, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008; 12:86-94
19. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36:368-371
20. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011; 6:e16475
21. Keller MJ, Carpenter CA, Lo Y, et al. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: Candidate antimicrobial contraceptive. PLoS One 2012; 7:e46901
22. Haberer JE, Robbins GK, Ybarra M, et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav 2012; 16:375-382
23. Deschamps AE, Wijngaerden EV, Denhaerynck K, et al. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr 2006; 43:247-248
24. Muchomba FM, Gearing RE, Simoni JM, et al. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr 2012; 61:490-498
25. Berg K, Wilson I, Li X, et al. Comparison of antiretroviral adherence questions. AIDS Behav 2012; 16:461-468
26. Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav 2013; 17:307-318
27. Haberer J, Psaros C, Baeten J, et al. High Adherence to Oral PrEP Is Associated With Lack of Infections in an Ancillary Study of Objective Adherence Monitoring and Counseling Among HIV Discordant Couples in Partners PrEP Study. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA, USA
28. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977
29. Berg K, Arnsten J. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43(suppl 1):S79